http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Applying Multi-Objective Planning in Low-Carbon Product Design
Tsai Chi Kuo,Hsiao Min Chen,Chia Yi Liu,Jui-Che Tu,Tzu-Chang Yeh 한국정밀공학회 2014 International Journal of Precision Engineering and Vol. No.
In low-carbon product design, product environment, as well as economic and manufacturing capabilities, should be considered simultaneously. The purpose of this paper is to improve the product carbon footprint calculation efficiency. This study not only considers cost, supplier manufacturing capacity, and transport modes of product components from the viewpoint of low-carbon product design, but it also provides information on product GHG values, design phase cost, as well as the product decisions made by enterprises. In this way, enterprise objectives about carbon footprints and product cost can be met. Based on the product life cycle and product category specifications, this study, following the actual industry process flow, collects and calculates data on GHG emissions of components within the product life cycle, cost and supplier production capacity. The aim is to determine the operational parameters and constraint equations. Multi-objective planning is used to establish a low carbon optimal evaluation model. By reviewing carbon emissions in each phase, the study further determines whether or not to modify product structure and consumption in order to improve the efficiency of product carbon footprint calculation, reduce R&D cost, and help enterprises design low-carbon products. Finally, the findings are used for a case analysis.
( Ming-lung Yu ),( Ming-lun Yeh ),( Chi-yi Chen ),( Pin-nan Cheng ),( Ming-jong Bair ),( Jyh-jou Chen ),( Ching-chu Lo ),( Chi-ming Tai ),( Ching-yang Tsai ),( Kuo-chih Tseng ),( Chien-hung Chen ),( C 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Insufficient data regarding the treatment strategy for partial response to nucleot(s)ide analogue (NUC) raised the aim of investigating tenofovir alafenamide (TAF) switching for chronic hepatitis B (CHB) patients with advanced fibrosis and partial response to other NUCs. Methods: CHB patients with advanced fibrosis (stage 3 or 4) and under NUC (except TAF) therapy with detectable hepatitis B virus (HBV) DNA for >52 weeks are enrolled to TAF 25 mg/day for 96 weeks. The objectives are viral suppression, alanine aminotransferase (ALT) normalization and safety. Results: From Feb. 2019, 34 patients, including 21 (61.8%) with entecavir, 10 (29.4%) TDF and 3 (8.8%) lamivudine or adefovir, were enrolled (15 [44.1%] male, median 53 years). The fibroscan demonstrated a mean of 10.5 kPa (7 [20.6%] cirrhotic). Sixteen (47.1%) patients were HBV e antigen positive, seven (20.6%) had YMDD mutation. The median HBV DNA level declined from 68.5 IU/mL at enrollment to 27.0 IU/mL at 4<sup>th</sup> week, and undetectable at 12<sup>th</sup>, 24<sup>th</sup>, 36<sup>th</sup> week, respectively, after TAF switching, with undetectable HBV DNA in 14/34 (41.2%), 17/33 (51.5%), 15/25 (60.0%), and 9/15 (60.0%) patients and rate of ALT normalization (≤40 U/L) of 85.3%, 85.3%, 84.8%, 92.0%, and 80.0%, respectively, after TAF switching. (figure 1) Two patients experienced transient virological breakthrough and another one developed at the final time follow up. Serum creatinine and eGFR levels were stable after TAF switching (figure 1). Two patients early terminated including one at 12<sup>th</sup> week due to personal reason, and another one accidently died at 20<sup>th</sup> week due to acute heart attack. Others suffered only mild degrees of adverse events which were considered unrelated to treatment. Conclusions: The preliminary results demonstrated the TAF switching is effective and safe in viral suppression for CHB patients with advanced fibrosis and partial virologic responses to other NUCs.
Ginsenoside Rg3 ameliorates allergic airway infl ammation and oxidative stress in mice
Wen-Chung Huang,Tse-Hung Huang,Kuo-Wei Yeh,Ya-Ling Chen,Szu-Chuan Shen,Chian-Jiun Liou 고려인삼학회 2021 Journal of Ginseng Research Vol.45 No.6
Background: Ginsenoside Rg3, isolated from Panax ginseng, has anti-inflammatory and anti-tumor activities. It is known to reduce inflammation in acute lung injury in mice, and to reduce the expression ofinflammatory cytokines and COX-2 in human asthmatic airway epithelium. In this study, we attemptedto determine whether ginsenoside Rg3 inhibits airway inflammation, oxidative stress, and airwayhyperresponsiveness (AHR) in the lungs of asthmatic mice. We also investigated its effects on oxidativestress and the inflammatory response in tracheal epithelial cells. Methods: Asthma symptoms were induced in female BALB/c mice sensitized with ovalbumin (OVA). Micewere divided into five groups: normal controls, OVA-induced asthmatic controls, and asthmatic micetreated with ginsenoside Rg3 or prednisolone by intraperitoneal injection. Inflammatory BEAS-2B cells(human tracheal epithelial cells) treated with ginsenoside Rg3 to investigate its effects on inflammatorycytokines and oxidative responses. Results: Ginsenoside Rg3 treatment significantly reduced eosinophil infiltration, oxidative responses,airway inflammation, and AHR in the lungs of asthmatic mice. Ginsenoside Rg3 reduced Th2 cytokineand chemokine levels in bronchoalveolar lavage fluids and lung. Inflammatory BEAS-2B cells treated withginsenoside Rg3 reduced the eotaxin and pro-inflammatory cytokine expressions, and monocyteadherence to BEAS-2B cells was significantly reduced as a result of decreased ICAM-1 expression. Furthermore, ginsenoside Rg3 reduced the expression of reactive oxygen species in inflammatory BEAS-2B cells. Conclusion: Ginsenoside Rg3 is a potential immunomodulator that can ameliorate pathological featuresof asthma by decreasing oxidative stress and inflammation
Tsai, Huang-Wen,Hsieh, Fu-Chien,Chang, Chih-Chun,Su, Ming-Jang,Chu, Fang-Yeh,Chen, Kuo-Hsin,Jeng, Kuo-Shyang,Chen, Yun Asian Pacific Journal of Cancer Prevention 2015 Asian Pacific journal of cancer prevention Vol.16 No.17
Background: Orthotopic organ transplantation, a treatment option for irreversible organ dysfunction according to organ failure, severe damaged organ or malignancy in situ, was usually accompanied with massive blood loss thus transfusion was required. We aimed to evaluate the adverse impact of blood transfusion on solid organ transplantation. Materials and Methods: From January, 2009 to December, 2014, patients who received orthotopic organ transplantation at Far Eastern Memorial Hospital medical center were enrolled. Clinical data regarding anemia status and red blood cell (RBC) transfusion before, during and after operation, as well as patient outcomes were collected for further univariate analysis. Results: A total of 105 patients who underwent orthotopic transplantation, including liver, kidney and small intestine were registered. The mean hemoglobin (Hb) level upon admission and before operation were $11.6{\pm}1.8g/dL$ and $11.7{\pm}1.7g/dL$, respectively; and the nadir Hb level post operation and the final Hb level before discharge were $8.3{\pm}1.6g/dL$ and $10.2{\pm}1.6g/dL$, respectively. The median units (interquartile range) of RBC transfusion in pre-operative, peri-operative and post-operative periods were 0 (0-0), 2 (0-12), and 2 (0-6) units, respectively. Furthermore, the median (interquartile range) length of hospital stay (LHS) from admission to discharge and from operation to discharge were 28 (17-44) and 24 (16-37) days, respectively. Both peri-operative and post-operative RBC transfusion were associated with longer LHS from admission to discharge and from operation to discharge. Furthermore, it increased the risk of post-operative septicemia. While peri-operative RBC transfusion elevated the risk of acute graft rejection in patients who received orthotopic transplantation. Conclusions: Worse outcome could be anticipated in those who had received massive RBC transfusion in transplantation operation. Hence, peri-operative RBC transfusion should be avoided as much as possible.